Supplementary Table 2 from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study
Year: 2023
Type: supplementary-materials
Abstract: Characterization of pre and post tx biopsies using Genefu and the PAM50 dataset. Paired biopsies (16/19) match with the clinical subtype of the patient's tumor at diagnosis. Treatment did not affect PAM50 subtype. Tx: therapy; HR: hormone-resistant; TNBC: triple-negative breast cancer.
Authors: Roisin M. Connolly, Huili Li, Rachel C. Jankowitz, Zhe Zhang, Michelle A. Rudek, Stacie C. Jeter, Shannon A. Slater, Penny Powers, Antonio C. Wolff, John H. Fetting, Adam Brufsky, Richard Piekarz, Nita Ahuja, Peter W. Laird, Hui Shen, Daniel J. Weisenberger, Leslie Cope, James G. Herman, George Somlo, Agustin A. Garcia, Peter A. Jones, Stephen B. Baylin, Nancy E. Davidson, Cynthia A. Zahnow, Vered Stearns
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361920841